Cancer Discovery

Papers
(The H4-Index of Cancer Discovery is 91. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Hallmarks of Cancer: New Dimensions3414
Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak1147
Therapeutic Targeting of the Tumor Microenvironment671
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System591
Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer433
Liquid Biopsy: From Discovery to Clinical Application417
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors394
The Next Decade of Immune Checkpoint Therapy372
Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level312
Tuning the Antigen Density Requirement for CAR T-cell Activity302
TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?293
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation244
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer242
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab236
Tumor-Infiltrating Natural Killer Cells225
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition224
Artificial Intelligence in Cancer Research and Precision Medicine223
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells216
Paradigms on Immunotherapy Combinations with Chemotherapy204
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors203
Modes of Regulated Cell Death in Cancer194
Diffuse Glioma Heterogeneity and Its Therapeutic Implications193
Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment192
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers189
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer178
Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer174
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade171
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy166
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited161
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes154
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial153
Metabolic Codependencies in the Tumor Microenvironment153
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)152
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition151
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC151
HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers151
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib149
Lower Airway Dysbiosis Affects Lung Cancer Progression147
Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation147
Metastasis-Initiating Cells and Ecosystems145
Development of Immunotherapy Combination Strategies in Cancer143
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer142
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention142
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors142
Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner140
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis139
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer138
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma137
Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy136
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response136
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence135
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers133
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer132
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer130
Targeting the p300/CBP Axis in Lethal Prostate Cancer129
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer128
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study127
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures125
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma123
The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis120
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease119
WNT as a Driver and Dependency in Cancer117
St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem116
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets115
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants113
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies111
Mobocertinib (TAK-788): A Targeted Inhibitor ofEGFRExon 20 Insertion Mutants in Non–Small Cell Lung Cancer110
Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer110
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade110
Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer107
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer105
Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer104
Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma104
Independent Drug Action in Combination Therapy: Implications for Precision Oncology103
Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer–Associated Fibroblasts100
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study99
Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas99
Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic99
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance98
Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast–Driven Nutritional Support and Immunosuppression97
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade97
Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy95
Synthetic Lethality in Cancer Therapeutics: The Next Generation95
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab95
TargetingMETDysregulation in Cancer93
Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers93
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy93
Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes92
Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy91
Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing91
A Procarcinogenic Colon Microbe Promotes Breast Tumorigenesis and Metastatic Progression and Concomitantly Activates Notch and β-Catenin Axes91
0.16764092445374